The cryopyrin-associated periodic syndrome (CAPS) is associated with an overproduction of interleukin-1. Canakinumab, an anti–interleukin-1β monoclonal antibody, was given to 35 patients with CAPS and was found to induce remission in most of the patients. The cryopyrin-associated periodic syndrome (CAPS) is associated with an overproduction of interleukin-1. Canakinumab, an anti–interleukin-1β monoclonal antibody, was given to patients with CAPS and was found to induce remission in most of the patients. The cryopyrin-associated periodic syndrome (CAPS) comprises a spectrum of apparently distinct, rare, inherited inflammatory disorders of increasing severity, including the familial cold autoinflammatory syndrome, the Muckle–Wells syndrome, and neonatal-onset multisystem inflammatory disorder (also known as the chronic infantile neurologic, cutaneous, and articular syndrome). Patients with these disorders have severe fatigue, fever, and influenza-like myalgia from infancy, together with chronic anemia and inflammation of the skin, eyes, bones, joints, and meninges. Clinical features include rash, conjunctivitis, arthritis, chronic meningitis, sensorineural deafness, and intellectual impairment. Systemic AA amyloidosis that causes renal failure and usually results in death within 5 to 10 years . . .